DiObex Begins Dosing Patients In Phase 2b Trial Of Type 2 Diabetes Drug

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM). [click link for full article]

More: continued here

Filed under: Clinical Trials on September 28th, 2007